Description
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for:
- the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
- received prior therapy for metastatic disease, or
- developed disease recurrence during or within six months of completing adjuvant therapy.
How to use:
- Administered as an infusion by a clinical expert who has been certified. Your primary care physician will determine which portion of the supplement is essential and how frequently you should take it.
- This will vary depending on the condition for which you are being treated and may change from time to time.
Caution & Warnings:
- Pulmonary Toxicity
- Hypersensitivity Reactions
- Hemorrhage
- Thrombocytopenia
- Neurotoxicity
Side Effects:
- Fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis.
Ingredients:
- Ado-trastuzumab emtansine (100mg)
Reviews
There are no reviews yet.